// App-Quantinova.ai

154 : Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.

Researchers

Presenter

  • Elizabeth Catherine Smyth

Principal Investigators

  • Alex Pearson

  • Clare Peckitt

  • Ian Chau

  • David J. Watkins

  • Naureen Starling

  • Sheela Rao

  • Angela Gillbanks

  • Elaine Kilgour

  • Katherine Anne Sumpter

  • Neil R. Smith

  • Ros Cutts

  • Claire Rooney

  • Anne L. Thomas

  • Mazhar A. Ajaz

  • Sue Chua

  • Gina Brown

  • Sanjay Popat

  • David Cunningham

Medical Centers

  • Royal Marsden, London, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

  • The Royal Marsden Hospital, London, United Kingdom

  • AstraZeneca Oncology Innovative Medicines, Macclesfield, United Kingdom

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • Leicester Royal Infirmary Haematology, Leicester, United Kingdom

  • Royal Surrey County Hospital, Guildford, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Fibroblast growth factor receptor

  • Fibroblast growth factor receptor 1

  • Fibroblast Growth Factor Receptor 2

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • AZD-4547

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Cohort

Phase

  • II

Study Id's

  • NCT01795768

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved